Introduction
============

Colorectal cancer (CRC) is the third most common malignancy and the third leading cause of cancer death worldwide. Malignant colonic obstruction (MCO) due to CRC occurs in 8 % to 29 % of patients, which is a gastrointestinal emergency requiring urgent decompression. If not adequately treated, MCO can lead to electrolytic fluid imbalance, bacterial translocation, colonic necrosis, and death [@JR1134-1] [@JR1134-2] [@JR1134-3] .

Surgery has been the primary treatment of MCO for decades although surgical morbidity and mortality are higher in emergency scenarios than in elective procedures [@JR1134-4] [@JR1134-5] [@JR1134-6] . In the mid-1990 s, endoscopic self-expanding metal stents (SEMS) emerged as a treatment for gastrointestinal surgical emergencies [@JR1134-7] [@JR1134-8] [@JR1134-9] , including MCO, and the first studies raised high expectations because use of stents could avoid surgical intervention such as colostomy, leading to reduced morbidity and mortality, possibly resulting in higher quality of life (QOL) [@JR1134-10] [@JR1134-11] .

Many studies, including 13 randomized controlled trials (RCTs) [@JR1134-12] [@JR1134-13] [@JR1134-14] [@JR1134-15] [@JR1134-16] [@JR1134-17] [@JR1134-18] [@JR1134-19] [@JR1134-20] [@JR1134-21] [@JR1134-22] [@JR1134-23] [@JR1134-24] and 20 meta-analyses, have reported results of colonic SEMS as a bridge to surgery. However, SEMS use with palliative intent is not well studied.

The aim of this study was to perform a systematic review and meta-analysis of RCTs comparing colonic SEMS versus emergency surgery (ES) for MCO in palliative patients. This was the first systematic review that included only RCTs in the palliative setting.

Methods
=======

Protocol and registration
-------------------------

A protocol was established and documented prior to initiating the study to specify eligibility criteria and analytical methods for the studies included in this systematic review and meta-analysis. This protocol can be accessed at <http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017082304>

Study selection
---------------

A literature search was performed using MEDLINE, EMBASE, the Cochrane Library, Scopus, LILACS, BVS, Cochrane Central Register of Controlled Trials (CENTRAL), and The Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases from March 2017 to November 2017, with no restriction regarding the idiom or the year of publication. The search results are shown in the supplementary material.

Complete manuscripts of all relevant studies published were retrieved, and reference lists were searched to identify any additional relevant papers. When more than one publication by the same group of investigators was available, the latest and most complete study was included in the analysis.

Reviews, meta-analysis, letters, editorials, abstracts, unpublished studies, case reports, and small case series were excluded.

Inclusion criteria
------------------

RCTs comparing colonic SEMS versus surgery for malignant large bowel obstruction in palliative patients were included.

Exclusion criteria
------------------

Studies reporting the following were excluded: stenting for benign stenosis; stents as a bridge to surgery; stents placed under fluoroscopic guidance alone by an interventional radiologist; inadequate data on outcome variables for the two techniques; and reports wherein the data were impossible to calculate from the published results.

Data extraction
---------------

Data were extracted by two authors (IB and BM) according to a predefined data extraction form. Disagreements were resolved by consulting with a third investigator.

Data regarding study characteristics, total number of patients included, characteristics of the study population, and the number of subjects in each group were collected. Clinical variables included the American Society of Anesthesiologists classification (ASA), tumor site, metastasis, the type of stent used, and technical and clinical success after stent placement.

Technical success (TS) was defined as successful stent placement across the stricture and its deployment. Clinical success (CS) was defined as adequate bowel decompression within 48 hours of stent insertion without the need for reintervention.

Primary outcomes included 30-day mortality, survival, CS, and early adverse events (from 0 to 30 days). Secondary outcomes included TS, stoma formation, intensive care unit (ICU) stay, and length of hospital stay.

Assessment of study quality
---------------------------

Four RCTs were included in the analysis. The quality of these studies was assessed by appliying the Jadad score and the Cochrane Collaboration\'s tool for assessing risk of bias ( [Table 1](#TB1134-1){ref-type="table"} ).

###### Methods used in therapeutic studies.

  **Study**                       **Clinical question**   **Adequacy randomization**   **Allocation concealment**   **Double-blinding**   **Dropouts (\< 20 %)**   **Characteristics, prognostics or demographic**   **Outcomes**   **Intent-to-treat**   **Sample size**   **Jadad**
  ------------------------------- ----------------------- ---------------------------- ---------------------------- --------------------- ------------------------ ------------------------------------------------- -------------- --------------------- ----------------- -----------
  Young, 2015 [@JR1134-10]        Yes                     Yes                          Yes                          No                    Yes                      No                                                Yes            Yes                   Yes               4
  Fiori, 2012 [@JR1134-25]        Yes                     Yes                          Yes                          No                    Yes                      Yes                                               Yes            Yes                   No                3
  Van Hooft, 2008 [@JR1134-26]    Yes                     Yes                          Yes                          No                    Yes                      No                                                Yes            Yes                   Yes               3
  Xinopoulos, 2004 [@JR1134-28]   Yes                     Nr                           Nr                           Yes                   Yes                      No                                                Yes            Yes                   No                3

Statistical analysis
--------------------

Regarding meta-analysis, the difference was calculated as the risk difference (RD) for the Cochran-Mantel-Haenszel test with a 95 % confidence interval (CI) dichotomous variables and as the mean difference (MD) with fixed effect using inverse variance with a 95 % CI for continuous variables. Semi-quantitative measures were described as arithmetic mean, standard deviation (SD), and results of Student's *t* -test analysis. All data were addressed in an intention-to-treat (ITT) analysis.

The RevMan 5 software (Review Manager Version 5.3.5: Cochrane Collaboration, Copyright © 2014) was used for the meta-analysis of primary and secondary outcomes. Student's *t* -test was used to compare the weighted arithmetic means survival, time stay on the ICU and hospital stay because the standard deviation of these data could not be extracted from most of the included studies. Heterogeneity was tested with the Q test for significance and with the inconsistency index (I ^2^ ), where a value \> 50 % was considered as substantial heterogeneity between studies. A funnel plot was generated and linear regression tests were performed excluding the studies that were located outside the funnel plot (outliers). Next, another meta-analysis was performed without the outliers. True heterogeneity was presumed and the random effects model was applied in case of persistent high heterogeneity or if outliers could not be detected.

Results
=======

A search of the literature yielded 32,048 records from all databases. In total, 27 trials were included in the initial selection of articles on surgery and stents; four studies were duplicates. Therefore, full texts of 23 studies were reviewed and 19 were excluded for one or more of the following reasons: the study was not a controlled clinical trial; SEMS was used as a bridge to elective surgery; or the study was irrelevant to this topic.

Finally, four RCTs were selected for this study including 125 patients ( [Fig.1](#FI1134-1){ref-type="fig"} ).

![ Search strategy [@OR1134-36] .](10-1055-a-0591-2883-i1134ei1){#FI1134-1}

Results of individual studies
-----------------------------

Characteristics and available data on the number of patients in each group, their ages, the location of neoplasia (i. e., colonic or rectal), metastasis, and ASA status for all included studies are summarized in [Table 2](#TB1134-2){ref-type="table"} .

###### Population characteristics.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                    Year   Total n   Tumor site          N site tumor (sems)   N site tumor (es)   Metastasis         Age        Sex ratio (m/f)   ASA                                        Follow-up                                                                                    
  ------------------------- ------ --------- ------------------- --------------------- ------------------- ------------------ ---------- ----------------- ------------------------------------------ ---------------------------------------- ---------- -------- ----------- ---------- -------- -----------
                                                                                                                              **SEMS**   **ES**            **SEMS**                                   **ES**                                   **SEMS**   **ES**               **SEMS**   **ES**   

  Fiori [@JR1134-25]        2012   22        Sigmoid\            7\                     7\                 Liver\              9\         9\               77.2 [1](#FN1134-1){ref-type="table-fn"}   76 [1](#FN1134-1){ref-type="table-fn"}    6/5        7/4     ASA I/II\   10\        10\      12 months
                                             Rectal              4                      4                  Lung\               2\         2\                                                                                                                       ASA III      1          1       
                                                                                                           Peritoneal          3          3                                                                                                                                                        

  Van Hooft [@JR1134-26]    2008   21        Rectosigmoid\       7\                     9\                 Lung\               6\         2\               61.5 ± 12.9\                               67.8 ± 12.3\                              4/7        7/3     NR          NR         NR       12 months
                                             Descending colon    4                      1                  Liver\             11\        10\               (42 ± 88)                                  (46 ± 81)                                                                                    
                                                                                                           Bone\               1\         1\                                                                                                                                                       
                                                                                                           Lymphatic\          3\         0\                                                                                                                                                       
                                                                                                           Others              1          0                                                                                                                                                        

  Young [@JR1134-10]        2015   52        Rectum\             5\                     6\                 Liver\             19\        21\               66\                                        67\                                      17/9       18/8     ASA I/II\   17\        11\      12 months
                                             Rectosigmoid\       9\                     5\                 Lung\               7\         8\               (41 -- 83)                                 (35 -- 86)                                                   ASA III      7         14       
                                             Sigmoid\            8\                    12\                 Peritoneal\         8\        11\                                                                                                                                                       
                                             Descending\         2\                     1\                 Retroperitoneal\    1\         1\                                                                                                                                                       
                                             Splenic flexure\    1\                     1\                 Bone\               0\         1\                                                                                                                                                       
                                             Transverse colon\   0\                     0\                 Brain               1          0                                                                                                                                                        
                                             Hepatic flexure\    1\                     0\                                                                                                                                                                                                         
                                             Ascending colon     0                      1                                                                                                                                                                                                          

  Xinopoulos [@JR1134-28]   2004   30        Rectosigmoid\       NR                    NR                  NR                 NR         NR                NR                                         NR                                        9/6        7/8     NR          NR         NR       NR
                                             Sigmoid                                                                                                                                                                                                                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR: Not reported.

Mean age .

Primary outcomes
----------------

Mortality rate was assessed in all of the included studies. Thirty-day mortality was 6.3 % in the SEMS group and 6.4 % in the ES group, but mortality rate did not statistically differ between the groups (RD: 0.00, 95 % CI: −0.10 -- + 0.10 I ^2^ : 0 %). Egger's linear regression test did not reveal any publication bias (bias = 0.03; *P*  = 0.98) ( [Fig. 2](#FI1134-2){ref-type="fig"} ). In three studies assessing survival, mean survival was 279 days in the SEMS group and 244 days in the ES group, with no statistically significant difference between groups (MD: 20.14, 95 % CI: −42.92 to + 83.21, I ^2^ : 44 %) ( [Fig. 3](#FI1134-3){ref-type="fig"} ). CS was higher in the ES group (96 %) than in the SEMS group (84 %) (RD: −0.13, 95 % CI: −0.23 to −0.02, I ^2^ : 51 %) (  [Fig. 4](#FI1134-4){ref-type="fig"} ). Data regarding 30-day adverse events (AEs) were available for all four studies, with no statistically significant difference between the groups regarding AEs (RD: 0.18, 95 % CI: −0.19 to + 0.54, I ^2^ : 87 %) ( [Fig. 5](#FI1134-5){ref-type="fig"} ).

![ Mortality in 30 days.](10-1055-a-0591-2883-i1134ei2){#FI1134-2}

![ Survival.](10-1055-a-0591-2883-i1134ei3){#FI1134-3}

![ Clinical success.](10-1055-a-0591-2883-i1134ei4){#FI1134-4}

![ Early adverse events (30 days).](10-1055-a-0591-2883-i1134ei5){#FI1134-5}

Secondary outcomes
------------------

TS was compared using ITT analysis, slightly favoring the ES group (RD: −0.13, 95 % CI: −0.23 to −0.02 I ^2^ : 51 %) ( [Fig. 6](#FI1134-6){ref-type="fig"} ).

![ Technical success: intent-to-treat.](10-1055-a-0591-2883-i1134ei6){#FI1134-6}

Stoma formation was higher in the ES group, in which 86.1 % of the patients underwent a definitive colostomy compared to 14.3 % of patients in the SEMS group (RR: 0.19, 95 % CI: 0.11 -- 0.33, I ^2^ : 28 %) ( [Fig. 7](#FI1134-7){ref-type="fig"} ). Three studies reported ICU admission after treatment and corresponding information from the fourth article was acquired from the author [@JR1134-25] . Meta-analysis revealed no statistically significant difference between the groups (MD: −0.01, 95 % CI: −0.08 to + 0.05, I ^2^ : 7 %) ( [Fig. 8](#FI1134-8){ref-type="fig"} ). All studies reported the length of hospital stay ( [Fig. 9](#FI1134-9){ref-type="fig"} ). In case of high heterogeneity (I ^2^ : 74 %), funnel plot ( [Fig. 10](#FI1134-10){ref-type="fig"} ) analysis was performed to detect an outlier study [@JR1134-26] , and heterogeneity decreased after removal of that study (I ^2^ : 56 %) ( [Fig. 11](#FI1134-11){ref-type="fig"} ). Mean hospital stay was 17.5 days in the SEMS group and 35.5 days in the ES group, with an overall MD of −5.16 (95 % CI: −6.71 to −3.61, I ^2^ : 56 %).

![ Stoma formation.](10-1055-a-0591-2883-i1134ei7){#FI1134-7}

![ Time stay on the intensive care unit.](10-1055-a-0591-2883-i1134ei8){#FI1134-8}

![ Hospital stay with outlier.](10-1055-a-0591-2883-i1134ei9){#FI1134-9}

![ Hospital stay: funnel plot.](10-1055-a-0591-2883-i1134ei10){#FI1134-10}

![Hospital stay without outlier.](10-1055-a-0591-2883-i1134ei11){#FI1134-11}

Perforation was the most commonly reported complication in SEMS patients, accounting for 42.8 % of all AEs (  [Fig.12](#FI1134-12){ref-type="fig"} ).

![Stent-related complications.](10-1055-a-0591-2883-i1134ei12){#FI1134-12}

Discussion
==========

For approximately three decades, colonic stents have been used to treat colonic malignancies either as a bridge to surgery or as a palliative measure [@JR1134-27] . The majority of RCTs that focused upon use of SEMS as a bridge to definitive surgery were published in the last decade; however, these studies reported conflicting results, triggering a large debate on the true efficacy of colonic SEMS.

The first RCT that included only palliative patients was published in 2004 [@JR1134-28] and showed promising results for use of SEMS compared to ES as definitive treatment for MCO. In that study, a TS of 93.3 % was reported in the SEMS group, with all patients remaining free of colonic obstruction until their death, which occurred at 6 to 18 weeks of SEMS placement. Stoma was performed in all patients undergoing ES, and there was no significant difference between the groups in terms of survival.

The most recent systematic review using RCTs of palliative patients also included data from those in whom SEMS was placed as a bridge to surgery and final treatment [@JR1134-3] ; thus these results should be interpreted with caution. The last systematic review regarding SEMS focused on its placement as a bridge to surgery and not as a definitive treatment for palliative patients [@JR1134-29] . The current study is the first systematic review that used only RCT (evidence 1A) including palliative patients with CRC.

ES may cause morbidity and may be related to worse health-related QOL because an ostomy is the most likely treatment for relieving an obstruction. Conversely, colonic stenting can result in perforation, obstruction and other fatal complications [@JR1134-10] [@JR1134-25] [@JR1134-26] [@JR1134-30] .

Because one of the goals for treating patients with advanced neoplasia is to prolong survival and maintain the best QOL possible, SEMS placement may enable patients to maintain a high QOL by avoiding colostomy or other surgical interventions [@JR1134-10] .

In 2014, the European Society of Gastrointestinal Endoscopy recommended use of SEMS as the method of choice in patients receiving palliative care on the basis of results of retrospective, case series, and non-comparative studies [@JR1134-2] .

Until the emergence of the first RCTs, use of SEMS for treating MCO was thought to reduce morbidity and mortality [@JR1134-31] and to induce less trauma compared with ES. However, this concept was not supported by the RCTs reporting use of SEMS as a bridge to surgery or by their respective meta-analyses.

In this study, we detected no statistical significance between the groups in terms of 30-day mortality (6.4 % for the SEMS group and 6.3 % for the ES group). Another meta-analysis [@JR1134-32] demonstrated a significant reduction in mortality in the SEMS group compared with the surgical intervention group. However, in that study, the authors included retrospective studies and non-RCTs, which could have led to selection bias (patients with better prognosis were selected for surgery, whereas those with worse clinical status were selected for stent placement).

Our study showed no significant statistical difference in terms of survival time between the groups, which is in agreement with results of previous meta-analyses [@JR1134-33] . Early complications of stents included perforation, migration, and obstruction, which were observed in 36.5 % of patients. Surgical complications included non-functioning ostomy, suture dehiscence, intestinal volvulus, which were observed in 24.1 % of patients. Contrary to the findings of Takahashi et al., [@JR1134-32] SEMS placement did not reduce risk of early complications as demonstrated by Liang et al. [@JR1134-11] .

As expected, the ES group showed favorable results regarding CS but at the cost of a higher risk of colostomy (86.1 % vs 14.3 %). Despite lower CS rates in the SEMS group, there was no significant increase in the number of early AEs in these patients.

The reported difficulty in the SEMS group was related to performance of the guidewire technique, and the procedure was suspended if there was no success [@JR1134-10] [@JR1134-25] [@JR1134-26] [@JR1134-28] .

Although the ES group showed a 13 % superior technique and CS, patients in the SEMS group still had the possibility of surgical intervention if there was a therapeutic failure of both emergency surgery and follow-up [@JR1134-25] [@JR1134-28] [@JR1134-34] . Overall, in 9 of the 63 patients randomized to the SEMS group, the technique used had failed; thus, these patients were allocated to the ES group.

Long-term patency of colorectal stents is a matter of concern because obstruction or dislodgment can occur. Late stent dysfunction is reported in up to 19 % of patients undergoing stent placement. However, stent dysfunction is typically treated by tunneling with argon plasma coagulation, laser, or further stenting [@JR1134-10] [@JR1134-25] [@JR1134-26] [@JR1134-28] [@JR1134-34] [@JR1134-35] .

The main limitation of this study was the paucity of data regarding use of SEMS in palliative settings. Only four RCTs on use of SEMS in the palliative scenario were included in this analysis, from which the data were derived. Lack of standardization, such as post-procedure QOL analysis, could not be meta-analyzed owing to the unavailability of a dedicated evaluation questionnaire.

Conclusion
==========

Results of this meta-analysis indicate that mortality, mean survival, length of ICU stay, and early complications were similar for both SEMS use and ES. Surgery was associated with higher CS, whereas SEMS corresponded with shorter hospital stay and less permanent stoma. Further studies are required to address whether QOL is affected by any of these treatments.

SEMS may be an alternative for managing patients with unresectable obstructive CRC, with the advantage of early hospital discharge and shortened hospitalization time in relation to patients undergoing surgery as well as the main objective in patients receiving palliative care: survival with QOL being able avoid a colostomy.
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